多发性硬化疾病修正治疗进展

Advances in disease-modifying therapy for multiple sclerosis

疾病修正治疗(disease-modifying therapy,DMT)是多发性硬化(multiple sclerosis,MS)缓解期减少复发、改善预后的标准治疗。目前多种不同作用靶点和机制的DMT药物已在国内获批上市。随着对MS疾病机制的认识不断加深,对MS治疗目标的不断提高,多种新型药物也在积极开展临床试验,以追求更佳的疗效,更好的安全性。本文将对国内已获批DMT药物的作用机制、临床试验结果进行介绍,并对几种新型DMT药物的研究现状进行综述。

Disease-modifying therapy(DMT)is the standard therapy for reducing recurrence and improving prognosis during the remission stage of multiple sclerosis(MS).A variety of DMT drugs with different action targets and mechanisms have been approved and marketed in China.With a deeper understanding of the pathophysiology of MS and the improvement of the treatment goals for MS,clinical trials are being conducted for several novel drugs to pursue better efficacy and safety.This article introduces the mechanism of action and clinical trial results of the DMT drugs approved in China and reviews the current research status of several new DMT drugs.